申请人:Tatani Kazuya
公开号:US20070179115A1
公开(公告)日:2007-08-02
The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like.
In the formula, n is 1 or 2; R
A
is a hydrogen atom or a hydroxyl group; R
1
is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R
2
to R
4
, P
1
and Q represents a halogen atom, a cyano group or the like.
本发明提供了一种用于与血浆尿酸水平异常相关疾病的8-修饰嘌呤核苷衍生物。以下式(I)所代表的一种8-修饰嘌呤核苷衍生物、其前药或药用盐、或其水合物或溶剂化合物,对于痛风、高尿酸血症、尿路结石、高尿酸性肾病等的预防或治疗具有用处。在该式中,n为1或2;RA是氢原子或羟基;R1是氢原子、羟基、硫醇基、氨基或氯原子;环J代表可选地取代的2-萘基,或由以下一般式(II)所代表的基团,其中Y代表单键或连接基团;环Z代表可选地取代的芳基或杂环芳基等;而R2至R4、P1和Q代表卤素原子、氰基或类似物。